Harnessing new mHealth technologies to Strengthen the Management of Multidrug-Resistant Tuberculosis in Vietnam (V-SMART trial): a protocol for a randomised controlled trial

Harnessing new mHealth technologies to Strengthen the Management of Multidrug-Resistant Tuberculosis in Vietnam (V-SMART trial): a protocol for a randomised controlled trial.

Full text not available from this repository.
Item Type: Article
Official URL: https://doi.org/10.1136/bmjopen-2021-052633
Journal or Publication Title: BMJ Open
Volume: 12
Number: 6
Page Range: e052633
Date: 22 July 2022
Divisions: Tuberculosis
Depositing User: General Admin
Identification Number: 10.1136/bmjopen-2021-052633
ISSN: 2044-6055
Date Deposited: 08 Jan 2023 23:07

Introduction: Multidrug-resistant tuberculosis (MDR-TB) remains a major public health problem globally. Long, complex treatment regimens coupled with frequent adverse events have resulted in poor treatment adherence and patient outcomes. Smartphone-based mobile health (mHealth) technologies offer national TB programmes an appealing platform to improve patient care and management; however, clinical trial evidence to support their use is lacking. This trial will test the hypothesis that an mHealth intervention can improve treatment success among patients with MDR-TB and is cost-effective compared with standard practice.

Methods and analysis: A community-based, open-label, parallel-group randomised controlled trial will be conducted among patients treated for MDR-TB in seven provinces of Vietnam. Patients commencing therapy for microbiologically confirmed rifampicin-resistant or multidrug-resistant tuberculosis within the past 30 days will be recruited to the study. Participants will be individually randomised to an intervention arm, comprising use of an mHealth application for treatment support, or a 'standard care' arm. In both arms, patients will be managed by the national TB programme according to current national treatment guidelines. The primary outcome measure of effectiveness will be the proportion of patients with treatment success (defined as treatment completion and/or bacteriological cure) after 24 months. A marginal Poisson regression model estimated via a generalised estimating equation will be used to test the effect of the intervention on treatment success. A prospective microcosting of the intervention and within-trial cost-effectiveness analysis will also be undertaken from a societal perspective. Cost-effectiveness will be presented as an incremental cost per patient successfully treated and an incremental cost per quality-adjusted life-year gained.

Ethics: Ethical approval for the study was granted by The University of Sydney Human Research Ethics Committee (2019/676).

Dissemination: Study findings will be disseminated to participants and published in peer-reviewed journals and conference proceedings.

Trial registration number: ACTRN12620000681954.

Keywords: public health; respiratory medicine (see thoracic medicine); tuberculosis.

Velen, Kavindhran
Nguyen, Viet Nhung
Nguyen, Binh Hoa
Dang, Tho
Nguyen, Hoang Anh
Vu, Dinh Hoa
Do, Thu Thuong
Pham Duc, Cuong
Nguyen, Huu Lan
Pham, Huu Thuong
Marais, Ben J
Johnston, James
Britton, Warwick
Beardsley, Justin
Negin, Joel
Wiseman, Virginia
Marks, Guy Barrington
Nguyen, Thu Anh
Fox, Greg J
Last Modified: 08 Jan 2023 23:07
URI: https://eprints.centenary.org.au/id/eprint/1320

Actions (login required)

View Item View Item